Document:

EXHIBIT 10.6 Letter of Intent with Oncology Sciences Corporation,
             November 6, 2003

                                November 6, 2003

Dr. Tony Milici GeneThera, Inc.
3930 Youngfield Street
Wheatridge, CO 80033

Dear Dr. Milici:

     This letter evidences Oncology Sciences Corporation's (OSC) intent to enter
into a business agreement with GeneThera, Inc. (GTHA) to develop tumor marker
p65 diagnostic tests. The ultimate goal of this relationship is to develop two
assays in parallel: one ELISA-based and one real-time PCR based. The mutual
desire is to sell test kits (ELISA) to the research community to perform assays
on-site and to offer real-time PCR assays at GTHA (and/or at a to-be-determined
partner CLIA lab) on a fee-for-service basis. OSC will aid, ultimately, in the
marketing of such tests. Data for FDA approval will also be acquired and
compiled during the process.

     For the next 30 days, GTHA will, at its expense, and with the help of Drs.
Slaga and Hanausek, perform certain experiments with the real-time PCR system
using whole-blood samples and cell culture samples to assess feasibility of
building an assay system with other GTHA technology.

     During this period GTHA will also gather information from its target
investment community as to whether this development project between the
companies will generate financial interest and thereby result in investment in
GTHA. The resulting investment would be used by GTHA to pay OSC a license fee;
to pay the necessary development costs for AMC Cancer Research Center (through a
sponsored research agreement with OSC and AMC); to pay other related development
costs for GTHA; to seek an OEM manufacturing company for the ELISA kit; and to
seek CLIA lab acquisition or partnership opportunities.

     OSC warrants that is the exclusive licensee of United States Patents
     5,310,653, 5,411,868, and 5,773,215 (the "p65 technology"). OSC agrees to
     maintain its rights with the licensor of the p65 technology during the
     option period of 30 days.

     It is specifically understood by the parties hereto that this is only a
letter of intent and is not the actual contract for licensing and subsequent
development of the p65 assays. If the scientific outcome and the financial
interest-screening outcome are both favorable, then GTHA and OSC will attempt to
enter into an agreement which may or may not include, among other things, the
following:

     o    GTHA will seek a to-be-determined amount in investment for this
          project
     o    OSC will grant GTHA a sublicense to the p65 technology, subject to the
          terms and conditions of the license agreement governing OSC's rights
          to the p65 technology
     o    GTHA shall pay OSC a license fee payment of 200,000 shares of GTHA
          common stock
     o    GTHA will pay OSC $250,000 over a 12 month period for the ELISA
          development - to be used by OSC in a sponsored research agreement with
          AMC
     o    GTHA shall invest a to-be-determined amountin real-time PCR assay
          development for the p65 technology
     o    GTHA shall invest a minimum of $100,000 to work on manufacturing/scale
          up with partner for commercialization of ELISA kits (format, labeling,
          instructions, etc.)
     o    GTHA shall invest a minimum of $150,000 for marketing and training
          materials for commercialization of both tests
     o    OSC and GTHA will agree to a to-be-determined profit split upon
          commercialization of the kits
     o    In the event new intellectual property is developed (e.g. a rnai
          therapeutic), such inventions will be owned jointly by OSC and GTHA.

<PAGE>

Please contact me if you have any questions.

                                      Sincerely,

                                      Alan D. Andrews,
                                      Vice President

Please indicate your agreement to the terms of this letter of intent with your
signature below:

Dated:   November _______, 2003

By:___________________________
Dr. Tony Milici, President
GeneThera, Inc.Filed by Automated Filing Services Inc. (604) 609-0244 - Ikon Gear International, Inc. - Exhibit 10.1

LICENSE AGREEMENT

 THIS LICENSE AGREEMENT is made as of February 25, 2004 by
  and between Ikona Gear International, Inc., a Nevada Corporation (including
  Aircast Incorporated, a New Jersey Corporation (“Licensee”),“Party”
  and “Parties”.

         BACKGROUND

         Licensor
  has rights to the Licensed Patents, as defined below.

         Licensee
  wishes to obtain a license under the Licensed Patents to practice the methods
  and processes described and claimed in the

  Licensed Patents and to make, have made, use and sell Licensed Products, as
  defined below.

         Licensor
  wishes to grant such a license to Licensee on the terms and conditions of this
  Agreement. 

          Licensor
  and Licensee have therefore agreed as follows. 

 1.  DEFINITIONS 

          The
  following terms shall have the meanings indicated in this Agreement: 

          1.1.
  “Agreement” means this Agreement, hereto. 

          1.2.
  “Affiliate” means any company, corporation, controlling,
  or under common control with either Licensee or Licensor. For this purpose,
  “control” means direct or indirect beneficial the voting stock (or
  the equivalent) of such corporation or other business or having the right to
  direct, appoint or remove a majority or more of the members of its board of
  directors (or their equivalent), or having the power to control the general
  management of such company, corporation, business or entity, by contract, law
  or otherwise. Specifically, Licensor includes Ikona Gear Corp., a Canadian subsidiary
  company, and Ikona Gear USA, Inc., a US subsidiary company that holds the Licensed
  Patents. 

          1.3.
  “Confidential Information” means any and all including all
  information relating to any technology, product, method, process or intellectual
  property of such Party (including, but not limited to, owned or licensed intellectual
  property rights, data, know-how, samples, technical and non-technical materials
  and specifications) as well as any business plan, financial information, research
  data or results, or other confidential commercial information of or about such
  Party. Notwithstanding the foregoing, information of or about a Party shall
  not be considered Confidential Information with respect to such Party to the
  extent that the Person possessing such information can demonstrate by written
  record or other suitable physical evidence that: 

	 	(i) 	such information was lawfully in to the time such
        information was disclosed to such Person by the Party to whom the information
        relates; 

	 	 	 
	 	(ii) 	such information was developed by such Person independently
        of and without reference to Confidential Information; 

	 	 	 
	 	(iii) 	such information was lawfully obtained by such Person
        from a third party under no obligation of confidentiality to the Party
        to whom such information relates; or 

	 	 	 
	 	(iv) 	such information was at the time it was disclosed
        or obtained by such Person, or thereafter became, publicly known otherwise
        than through a breach by such Person of such Person's such information
        relates. 

         1.4.
  “FDA” means the United States Food and 1.5. “ Licensed
  Improvement Patents” means any U.S. or application covering inventions
  made, in whole or in part, by Licensor that claims an improvement to the inventions
  claimed or disclosed in the Licensed Scheduled Patents. 

          1.6.
  “Licensed Patents” means the Licensed Scheduled Improvement
  Patents. 

          1.7.
  “ Licensed Product” means, ith respect to a given country,
  any medicalw equipment containing the Ikona Gear and functioning as or providing
  the functional equivalent of a human joint brace product the manufacture, regulatory-approved
  use or sale of which would, absent the license granted by Licensor to Licensee
  herein, infringe any Valid Claim of any Licensed Patent in that country. All
  Licensed Product shall clearly identify the Ikona Gear as "Ikona Gear Patented
  Technology". 

         1.8.
  “Licensed Scheduled Patents” means any of international patents
  those U.S. and patent applications described on Schedule 1.8 and
  any divisional, continuation or continuation-in-part thereof or substitute therefor,
  any foreign patent applications corresponding to any such patent applications,
  and any U.S. or foreign patent or the equivalent thereof issuing there from
  or any reissue, renewal or extension thereof. 

         1.9.
  “Net Sales” means in any case where any commercially disposed
  of by Licensee ngth sale to anor its independent third party, the number
  of units sold for such Licensed Product, less permitted deductions for credit
  or allowance units given or made for rejections or return of any previously
  sold Licensed Product. Transfers of Licensed Products intended solely for use
  as samples or noncommercial testing or clinical trials without financial remuneration
  to Licensee or its Sublicensees shall be excluded from Net Sales. 

         1.10.
  “Party” means each party to this Agreement and permitted
  assigns. 

- - 2 - -

          1.11.
  “Person” means any natural person or legal 

         1.12.
  “PMA or equivalent” means (a) a single premarket premarket
  approval applications for regulatory approval to market and sell a Licensed
  Product in the United States, filed by Licensee with the FDA or any successor
  agency having the administrative authority to regulate the approval for marketing
  and sale of new medical device products, or (b) any application or notification
  comparable to those set forth in (a) that may be filed in any country with regulatory
  authorities having jurisdiction comparable to that of the FDA. 

         1.13.
  “Regulatory Approval” means, as applicable, (a) or equivalent
  and satisfaction of related applicable FDA registration and notification requirements
  (if any) or, in any foreign country, approval by regulatory authorities having
  jurisdiction over such country of a PMA or equivalent filed by Licensee together
  with any other approval, certification and/or registration necessary to make
  and sell in such country a Licensed Product, including, where applicable, satisfactory
  labeling and pricing approval, and, if necessary for commercialization of the
  such Licensed Product, governmental or third party reimbursement approval and/or
  inclusion of the Licensed Product on any governmental formularies effective
  in such country. 

          1.14.
  “Sublicensee” means any Person to whom or all of the rights
  granted to Licensee under this Agreement. 

          1.15.
  “Valid Claim” m eans a claim of an issued and unexpired patent
  that has not been held permanently revoked, unenforceable or invalid by a decision
  of a court or other government agency of competent jurisdiction, unappealable
  or unappealed within the time allowed for appeal, and that has not been admitted
  to be invalid or unenforceable through reissue or disclaimer or otherwise. 

 2.  LICENSE 

          2.1.
  Grant of License. Licensor hereby grants to Licensee for the term of
  this Agreement, an exclusive, worldwide, royalty-bearing license under the Licensed
  Patents, including the right to grant sublicenses, to practice all methods and
  processes claimed or disclosed in the Licensed Patents as applicable in the
  field of medical equipment containing the Ikona Gear and functioning as or providing
  the functional equivalent of a human joint brace, and to make, have made, use,
  offer to sell and sell Licensed Products. 

          2.2.
  Sublicensing. Licensee shall have the right to grant sublicenses consistent
  with the terms and conditions of this Agreement; provided, however,
  that Licensee shall be responsible for the operations of any sublicensee relevant
  to this Agreement as if such operations were carried out by Licensee itself,
  including (without limitation) the payment of any royalties or other payments
  provided for hereunder, regardless of whether the terms of any sublicense provides
  for such amount to be paid by the sublicensee directly to Licensor. Licensor
  shall be provided copies of any sublicensing agreements; provided, however,
  that Licensee may redact any portion of any such sublicensing agreement that
  does not specifically relate to the sublicense of the Licensed Patents. 

- - 3 - -

          2.3.
  Restriction on other Rights. No license is granted to any right not specifically
  listed or referenced in this Agreement. 

          3. 
  CONSIDERATION, RECORD-KEEPING AND PAYMENTS 

          3.1.
  Payments and Other Consideration. In exchange for execution of this Agreement,
  Licensee shall pay or cause to be paid to Licensor an up-front payment of US$10,000.
  Additionally, within thirty (30) days of the end of each calendar quarter in
  which any Net Sales occur, Licensee shall pay or cause to be paid to Licensor
  a royalty equal to US$2.50 per unit of all Net Sales of any arm brace, and a
  royalty payment for any other human joint brace which is proportional to the
  royalty of the arm brace (US$2.50) times the greater of (a) the wholesale price
  of the other human joint brace divided by the wholesale price of the arm brace,
  or (b) one (“Royalty Payments”). 

          3.2.
  Reports. Within thirty (30) days of the end of each calendar quarter,
  Licensee shall deliver to Licensor a true and accurate report, giving such particulars
  of the business conducted by Licensee and any Sublicensees during the preceding
  quarter under this Agreement as are pertinent to an accounting for any royalty
  or other payments hereunder. If no payments are due, it shall be so reported.
  For purposes of determining when a sale of Licensed Product occurs, the sale
  shall be deemed to occur on the date of invoice to the purchaser of the Licensed
  Product. 

          3.3.
  Termination of Obligation. Licensee's obligation to the Net Sale
  of any Licensed Product shall terminate on a country-by-country basis, upon
  the expiration of all Licensed Patents applicable to the manufacture, use or
  sale of such Licensed Product. 

          3.4.
  Records. During the term of this Agreement and for three years thereafter,
  Licensee shall keep complete and accurate Licensed Products and such other matters
  as may affect the determination of any amount payable to Licensor hereunder
  in sufficient detail to enable certified public accountants engaged by Licensor
  to determine any amounts payable to Licensor under this Agreement. Licensee
  shall permit certified public accountants engaged by Licensor, at Licensor's
  provided below), to examine not more than once in any twelve-month period its
  books, ledgers, and records during regular business hours for the purpose of
  and to the extent necessary to verify any report required under this Agreement
  or the accuracy of any amount payable hereunder. Licensee shall also permit
  Licensor or its representatives to examine periodically any documents relating
  to its sublicensing of the Licensed Patents during regular business hours. 

          3.5.
  Form of Payment; Taxes. All amounts payable to Licensor hereunder shall
  be payable in United States funds without deductions for taxes, assessments,
  fees, or charges of any kind. Licensee shall be responsible for the payment
  of all withholding taxes imposed by any country on any royalty or other payment
  payable to Licensor hereunder and the percentage or other amounts payable to
  Licensor hereunder shall not be reduced to reflect the payment of any such withholding
  tax. All amounts payable to Licensor hereunder shall be payable in United States
  dollars at such place as Licensor may reasonably designate. 

- - 4 - -

 4.  PROTECTION OF INTELLECTUAL PROPERTY RIGHTS  

          4.1.
  Patent Prosecution. Licensor shall provide written notice to Licensee
  of the conception or reduction to practice of any potentially patentable invention
  that could be the subject of an application for a Licensed Improvement Patent
  within ten (10) days after such conception or reduction to practice. In addition,
  Licensor shall inform Licensee of any matters that may affect the preparation,
  filing, prosecution and maintenance of such patents or patent applications.

          4.2.
  Confidential Information. Each Party shall maintain the Confidential
  Information of the other Party in confidence, and shall not disclose, divulge
  or otherwise communicate such Confidential Information to others, or use it
  for any purpose, except pursuant to, and in order to carry out, the terms and
  objectives of this Agreement or with the express written consent of Party who
  provided such Confidential Information. Each Party also hereby agrees to prevent
  and restrain the unauthorized disclosure of such Confidential Information by
  any of its directors, officers, employees, consultants, sub-contractors, sub-licensees
  or agents. The provisions of this paragraph shall not apply to any Confidential
  Information of a Party which is required to be disclosed by another Party to
  comply with any applicable laws or regulations, but only to the extent required
  by such law or regulation and further provided that the Party making any disclosure
  pursuant to the provisions of this sentence shall provide prior written notice
  of such disclosure to the other Party sufficiently in advance of such disclosure
  to allow such other Party to respond and to take reasonable and lawful action
  to avoid and/or minimize the degree of such disclosure. Notwithstanding the
  foregoing, Licensee shall be permitted to provide to applicable regulatory authorities
  any information provided to Licensee pursuant to Section 5.2 for the purposes
  set forth therein. 

          4.3.
  Infringement by Third Parties. Each Party shall promptly advise the other
  in writing of any infringement or suspected infringement of any of the rights
  under the Licensed Patents licensed hereby that Licensed Rights cover a Licensed
  Product (the Licensed Rights”) by a third party (an "Infringement").
  In the case of any Infringement of any Licensed Rights by any third party (an
  “Infringer”) during the term of this Agreement, obligation,
  under Licensee's icensee's expense, to own control Infringement
  of the Licensed Rights, or to defend the Licensed Rights in any declaratory
  judgment action brought by third parties which alleges the invalidity, unenforceability
  or noninfringement of the Licensed Rights under the Licensed Patents and to
  otherwise enforce such Licensed Rights or such other intellectual property right.
  Licensor shall assist Licensee as reasonably requested, at Licensee's
  expense, Infringer. Any amount recovered as a result of any action taken by
  Licensee hereunder shall be first applied to reimbursing Licensee for its out-of-pocket
  expenses incurred in connection therewith and the remainder, if any, shall be
  divided appropriately between Licensee and Licensor with reference to the relative
  monetary injury suffered by each of them by reason of the infringement for which
  said amounts are recovered. If, following reasonable notice from the Licensor,
  Licensee shall fail to take any action against any Infringer which Licensor
  may reasonably deem necessary or desirable to prevent such Infringement, or
  to recover damages therefor, in addition to any other remedy available to it,
  Licensor may, upon notice to Licensee, take any steps Licensor may deem appropriate
  against such Infringer Licensee shall assist Licensor, at Licensor's 

- - 5 - -

 action against any such Infringer. Any amount recovered as
  a result of any such action taken by Licensor shall first be applied to reimbursing
  Licensor for its out-of-pocket expenses incurred in connection therewith and
  the remainder, if any, shall be divided appropriately between Licensee and Licensor
  with reference to the relative monetary injury suffered by each of them by reason
  of the infringement for which said amounts are recovered. Neither Party may
  settle or compromise any such suit or action for Infringement pursuant to this
  section without the written consent of the other Party, which consent shall
  not be unreasonably withheld or delayed. This paragraph shall survive the termination
  or expiration of this Agreement. 

          4.4.
  Infringement of Third Party Rights. Licensee shall promptly advise Licensor
  in writing of any notice or claim of any infringement and of the commencement
  against it of any suit or action for infringement of a third party patent made
  or brought against Licensee and based upon or arising under the license granted
  obligation to make royalty payments hereunder shall be suspended during the
  period such claim is outstanding, and Licensee shall have at all times the right
  either to:

	 	(i) 	request but not compel that Licensor enter into negotiation with such
      third party to obtain rights for Licensee under the third party patent;
	 	 	 
	 	(ii) 	request but not compel that Licensor defend such claim, suit or action
      at Licensor's expense; or 
	 	 	 
	 	(iii) 	provided neither action specified in subsections (i) and (ii) above have
      been taken by Licensor, and provided no settlement is reached with such
      third party within a reasonable time, terminate this Agreement. 

         Licensor
  shall not be obligated to enter into negotiations with such third party to obtain
  rights for Licensee under the third party patent nor obligated to defend such
  claim, suit or action. If Licensor, in its sole discretion, elects to enter
  into negotiations with such third party to obtain rights for Licensee under
  the third party patent or if Licensor, in its sole discretion, elects to undertake
  at its own expense the defense of any such claim, suit or action, Licensee shall
  render Licensor all reasonable assistance, at negotiations or in the defense
  of any such claim, suit or action. Licensor has the primary right to control
  the defense of any such claim, suit or action by counsel of its own choice,
  suit or action in respect of which Licensee is a defendant by counsel of its
  own choice. The Parties agree to cooperate reasonably in any such defense. 

          Notwithstanding
  the foregoing, if Licensor has not within 30 days (or such lesser period of
  time as is necessary to avoid entry of a default judgment against Licensor or
  Licensee) from the date of receipt of request from Licensee, either entered
  into negotiations with such third party to obtain rights for Licensee under
  the third party patent or initiated legal action to defend such claim, suit
  or action, Licensee shall have the right to enter into such negotiations or
  defend such claim, suit or action. Licensee shall be entitled to deduct all
  reasonable out-of-pocket expenses (including legal fees) incurred in entering
  into such negotiations or defending such claim, suit or action from royalties
  due Licensor. Licensee shall not settle or compromise any such suit or action
  without the written consent of Licensor, which consent shall not be unreasonably
  withheld or delayed. 

- - 6 - -

 5.  OPERATIONS UNDER THE LICENSE 

          5.1.
  Compliance with Law. Licensee shall comply with all government statutes
  and regulations that relate to Licensed Products, including, but not limited
  to, FDA statutes and regulations and the Export Administration amended, and
  the regulations promulgated thereunder, and any applicable similar laws and
  regulations of any other country. 

          5.2.
  Cooperation with Regulatory Filings and Approvals. Licensor shall, at
  Licensee's request and at no additional cost to Licensee, cooperate with Licensee
  and provide to Licensee all reasonable assistance and research data, research
  results and other information that Licensor possesses as necessary for Licensee
  to make regulatory filings, obtain and maintain regulatory approvals and satisfy
  other regulatory requirements, including any FDA filings, approvals and requirements,
  required in order for Licensee or any of its Sublicensees to develop, manufacture,
  commercialize and sell any proposed Licensed Product. Licensor further agrees
  not to make any such information available to any third party for the purpose
  of developing, manufacturing, commercializing or selling any medical equipment
  containing the Ikona Gear and functioning as or providing the functional equivalent
  of a human joint brace or for obtaining regulatory approvals in furtherance
  of any of the foregoing. 

 6.  INDEMNIFICATION; INSURANCE; WARRANTY DISCLAIMER 

	 	6.1. Indemnification. 

                6.1.1.
        Licensee shall indemnify, defend and hold harmless Licensor, its employers,
        their trustees, officers, medical and professional staff, employees, and
        agents and their respective successors, ndemnitee”),heirs liability,
        damage, loss, or expense litigation) to the extent incurred by or imposed
        upon any Indemnitee in connection with any claims, suits, actions, demands
        or judgments for death, illness, personal injury, property damage and
        improper business practices arising out of the manufacture, sale, use
        or other disposition of Licensed Products, provided, however, that, in
        each case, the Indemnitee gives prompt notice to Licensee of any such
        claim or action, tenders the defense of such claim or action to Licensee
        defending such claim or action and does not compromise or settle such
        claim or action without Licensee's prior written consent

                6.1.2.
        Licensee's indemnification under 6 liability, damage, loss or expense
        to the extent that it is attributable to the negligence, reckless misconduct
        or intentional misconduct of the Indemnitee or to a breach by Licensor
        of its obligations under this Agreement or to the extent that any delay
        by the Indemnitee to notify Licensee of any claim or ability to defend
        such claim or action. 

                6.1.3.
        Each Party (the "Indemnitor") shall indemnify, defend and hold harmless
        the other Party, its employers, their trustees, directors, officers, medical
        and professional staff, employees, and agents and their respective successors,
        heirs and assigns (each an 

- - 7 - - 

 

	 	“Indemnitee”), against , or expense (including
        reasonableany liability, attorneys' fees and expenses of litigation) Indemnitee
        as a result of or in connection with any actual or alleged breach or default
        by the Indemnitor of any representation, warranty or covenant of the Indemnitor
        set forth herein, provided, however, that, in each case,
        the Indemnitee gives prompt notice to the Indemnitor of any such claim
        or action, tenders the defense of such claim or action to the Indemnitor
        and assists the Indemnitor at Indemnitor's expense in defending such claim
        or action and does not compromise or settle such claim or action without
        Indemnitor's prior written consent. 

                6.1.4.
        An Indemnitor's indemnification under6.1.3 above shall not apply to any
        liability, damage, loss or expense to the extent that it is attributable
        to the negligence, reckless misconduct or intentional misconduct of an
        Indemnitee or to a breach by an Indemnitee (or if the Indemnitee is not
        the Licensor or the Licensee, then by the Licensor or the Licensee, as
        the case may be) of its obligations under this Agreement or to the extent
        that any delay by the Indemnitee to notify the Indemnitor of any claim
        or action adversely affects Indemnitor's rights or ability to defend such
        claim or action. 

                6.1.5.
        This Section 6.1 shall survive expiration or termination of this Agreement.
        

         6.2.
  Insurance. Licensee shall, at its sole cost and expense, either obtain
  or maintain in effect sufficient liability insurance to cover Licensee for its
  liability arising from the manufacture, use or sale of the Licensed Products.
  Licensee shall maintain such liability coverage continuously in effect during
  the term of this Agreement. Licensor shall not in any way, for any reason, be
  liable to Licensee or to any third party for legal claims arising from manufacture,
  use, application or sale of the Licensed Products by Licensee. Licensor shall,
  at its sole cost and expense, either obtain or maintain in effect sufficient
  liability insurance to cover Licensor for its liability arising from the malfunction
  of the gear due to elements of its design, gross negligence or intentional acts.
  However, Licensor shall not be responsible for any liability claims that may
  be made in respect of the Licensed Product because such liability risks directly
  result from a design modification -licensee, ION Design, LLC, as such areof
  Licensee's beyond the control of Licensor. 

          6.3. Representations
  and Warranties. Licensor hereby represents, warrants and covenants to Licensee
  as follows:

	 	(i) 	Licensor, to the best of its knowledge, is the sole
        and exclusive owner of the Licensed Patents and the sole and exclusive
        inventor of the inventions described therein; 

	 	 	 
	 	(ii) 	No third party has notified Licensor of any claim of
        infringement by Licensor, or any of its respective employees or consultants,
        of any patents or other intellectual property rights of others in connection
        with the methods or processes described in the Licensed Patents and to
        the best of Licensor's knowledge, the methods and processes described
        in the Licensed Patents does not infringe any patents or other intellectual
        property rights of others; and 

      

- - 8 - - 

 

	 	(iii)
 	No interference or opposition proceeding
        is pending or threatened relating to the Licensed Patents.

	 	 	 
	 	(iv)	To the best of Licensor's knowledge,
        this agreement by Licensor does not and will not conflict with, cause
        a default under or violate any existing contractual obligation that may
        be owed by Licensor to any third party.

	 	 	 
	 	7. TERM AND TERMINATION
	 
	
	7.1. Term. Unless
        terminated earlier under the provisions of this Agreement, this Agreement
        will expire when Licensee has no further obligation to make or cause to
        be made any Royalty Payment or Sublicensee Payments under Sections 3.1.1
        or 3.1.2 of this Agreement.

	 
	 	7.2. Termination by Licensor.
	 
	 	7.2.1. Licensor shall have
        the right to terminate this Agreement and the license granted hereunder
        upon the happening of any of the following events:

	 	 
	 	(i)	Licensee fails to pay or cause to be
        paid any royalty or other payment which has become due to Licensor under
        Section 3 of this Agreement, within sixty (60) days after receiving a
        written request from Licensor to make such payment or to cause such payment
        to be made;

	 	 	 
	 	(ii)	Licensee is in breach of or default
        under any other material provision of this Agreement and has not cured
        such breach or default within ninety (90) days after written notice from
        Licensor to Licensee specifying the nature of such breach or default.

	 	 	 

	 	7.3. Termination by Licensee. Licensee shall
        have the right to terminate this Agreement at any time upon ten notice.
        twenty (20) days'

	 	 
	 	7.4. Effect of Termination.
	 	 
	 	         7.4.1.
        Upon termination of this Agreement for any reason, nothing herein shall
        be construed to release either Party from any obligation that matured
        prior to the effective date of such termination.

	 	 
	 	         7.4.2.
        Upon any termination of this Agreement for any reason, the license granted
        under this Agreement shall terminate.

	 	 
	 	         7.4.3.
        The provisions of Sections 4.2 (Confidential Information), 4.3 (Infringement
        by Third Parties) (but only with respect to infringement occurring prior
        to termination), 6.1 (Indemnification), and 9 (General) shall survive
        termination of this Agreement for any reason.

	 	 
	 	          7.4.4.
        Licensee may, after termination of this Agreement, sell all Licensed Products
        which are in inventory at the time of termination, and complete and sell

- - 9 - - 

 

	 	Licensed Products which Licensee can clearly demonstrate
        were in the process of manufacture at the time of such termination, provided
        that Licensee shall pay to Licensor any royalties due on the sale of such
        Licensed Products and shall submit reports, in accordance with this Agreement.
      

	 	 
	 	         7.4.5.
        Upon termination of this Agreement for any reason, any sublicense not
        then in default shall continue in full force and effect, except that the
        Licensor shall be substituted in place of the Licensee for purposes thereof.
      

         7.5.
  Limitation of Liability on Termination. Upon termination of this Agreement
  by Licensee, Licensee shall have no obligation to Licensor for compensation
  or for damages of any kind, whether on account of the loss by Licensor of present
  or prospective sales, investments or goodwill, advertising costs, supplies,
  like or unlike items, and Licensor hereby waives any rights which may be granted
  to it by statute or otherwise which are not granted to it by this Agreement.

 8.  GENERAL 

          8.1.
  Assignment. This Agreement shall be binding upon and shall inure to the
  benefit of each Party and each Party's respective provided, however, that neither
  Party shall have the right to assign this Agreement or its rights and obligations
  hereunder to any other Person without the prior written consent of the other
  Party, except as expressly provided in this paragraph. Licensee may assign or
  otherwise transfer this Agreement and the license granted hereby and the rights
  acquired by it hereunder in connection with a sale or other transfer of such
  Party's entire license granted hereby relates, provided, in all such cases,
  that any such assignee or transferee has agreed in writing to be bound by the
  terms and provisions of this Agreement. Any purported assignment in violation
  of the provisions of this paragraph shall be null and void. 

          8.2.
  Entire Agreement/Amendments. This Agreement constitutes the entire and only
  agreement between the Parties relating to Licensed Patents, and all prior negotiations,
  representations, agreements and understandings are superseded hereby. No agreements
  amending, altering or supplementing the terms hereof may be made except by means
  of a written document signed by a duly authorized representative of each Party.

          8.3.
  Notices. Any notice, communication or payment required or permitted to
  be given or made hereunder shall be in writing and, except as otherwise expressly
  provided in this agreement, shall be deemed given or made and effective (i)
  when delivered personally; or (ii) when delivered by telex or telecopy (if not
  a payment); or (iii) when received if sent by overnight express or mailed by
  certified, registered or regular mail, postage prepaid, addressed to parties
  at their address stated below, or to such other address as such Party may designate
  by written notice in accordance with the provisions of this Section 8.3.

	 	LICENSOR:	Ikona Gear International, Inc. 

      Suite 810, 609 Granville Street 

      Vancouver, BC, V7Y1G5 

      ATTENTION: Laith Nosh 

- - 10 - - 

 

	 	LICENSEE: 	Aircast Incorporated

      92 River Road 

      Summit, NJ 07901

      ATTENTION: General Counsel 

         8.4.
  Governing Law; Jurisdiction. This Agreement shall be construed and enforced
  in accordance with the domestic substantive laws of the State of Colorado without
  regard to any choice or conflict of laws rule or principle. The United States
  District Court for the State of Colorado shall have jurisdiction over any disputes
  arising under this Agreement, and each of the Parties hereby consents to such
  Court's exercise of jurisdiction. If either Party to this Agreement breaches
  any of the terms of this Agreement, then that Party shall pay to the non-defaulting
  Party all of the non-defaulting Party's costs and expenses, including attorneys
  fees, incurred by that Party in enforcing the terms of this Agreement. 

          8.5.
  Headings. Headings included herein are for convenience only, and shall
  not be used to construe this Agreement. 

          8.6.
  Independent Contractors. For the purposes of this Agreement and all services
  to be provided hereunder, each shall be, and shall be deemed to be, an independent
  contractor and not an agent, partner, joint venturer or employee of the other
  Party. Neither Party shall have authority to make any statements, representations
  or commitments of any kind, or to take any action which shall be binding on
  the other Party, except as may be explicitly provided for herein or authorized
  in writing. 

          8.7.
  Use of Name. The Licensee agrees to display on its Licensed Product the
  logo of the Licensor and a phrase “patented Ikona suitable to both parties,
  and a reference to U.S. Patent No. 5,505,668. Both parties also agree to use
  the name of each other in press releases, public announcements or other publicity
  or advertising materials, providing written approval of the other Party. The
  Parties may agree on standard language that can be used in other public documents,
  which each Party may use without obtaining any subsequent consent from the other
  Party. 

          8.8.
  Severability. If any clause or provision of this Agreement shall be found
  by a court of competent jurisdiction or rendered or by operation of any applicable
  law to be void, invalid or unenforceable, the same shall either be reformed
  to comply with applicable law or stricken if not so conformable, so as not to
  affect the validity or enforceability of any other clause or provision of this
  Agreement, which shall remain in full force and effect. 

          8.9.
  Language. The language of this Agreement shall be English and the Parties
  hereby waive, and agree that this Agreement shall be valid and enforceable notwithstanding,
  any requirement that it be written in or translated into any language other
  than English. If, for any 

- - 11 - -

 reason, this Agreement is translated into a language other
  than English, the English language version shall be controlling for all purposes.

          8.10.
  UN Convention on Contracts for Sale of Goods. The Parties expressly agree
  that the United Nations Convention on Contracts for the International Sale of
  Goods shall not apply to this Agreement. 

          8.11.
  Force Majeure. Neither Party shall be responsible or liable to the other
  Party for nonperformance or delay in performance of any terms or conditions
  of this Agreement due to acts or occurrences beyond the control of the nonperforming
  or delayed Party, including, but not limited to, acts of God, acts of government,
  wars, riots, strikes or other labor disputes, shortages of labor or materials,
  fires, and floods, provided the nonperforming or delayed Party provides to the
  other Party written notice of the existence of and the reason for such nonperformance
  or delay. 

          8.12.
  No Waiver. Failure of either Party to enforce a right under this Agreement
  shall not act as a waiver of that right or the ability to later assert that
  right relative to the particular situation involved or to terminate this Agreement
  arising out of any subsequent default or breach. 

          8.13.
  Limitation of Liability. Except for indemnification for third party claims,
  neither Party shall be liable to the other Party for indirect, incidental or
  consequential damages arising out of any of the terms or conditions of this
  Agreement or with respect to its performance or lack thereof. 

          8.14.
  Counterparts. This Agreement may be executed in any number of counterparts,
  each of which shall constitute an original document, but all of which shall
  constitute the same agreement. 

          IN WITNESS
  WHEREOF, the parties have caused this Agreement to be executed by their duly
  authorized representatives as of the date first set forth above. 

	IKONA GEAR INTERNATIONAL,
        INC.

        Licensor 

        
	AIRCAST INCORPORATED

      Licensee 
	 	 	 	 
	By:	_________________________________	By:	_________________________________
	Name:	_________________________________	Name:	_________________________________
	Title:	_________________________________	Title:	_________________________________
	 	 	 	 
	 	 	 	 
	 	 	 	 

- - 12 - -

Schedule 1.8 

	LICENSED SCHEDULED PATENTS
	 	 	 	 
	The following patents and patent applications are the intended
      subject of this Agreement:
	 	 	 	 
	Jurisdiction of Issue	Patent Number	Countries Covered	Expiry Date
	 	 	 	 
	United States	5,505,668	United States	April 9, 2013
	 	 	 	 
	Canada	2,129,188	Canada	July 29, 2014
	 	 	 	 
	European Patent	0770192	France, Germany, Italy,	July 26, 2015
	Convention	 	Great Britain and Sweden	 
	 	 	 	 
	### END of SCHEDULE ###

-13-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00064-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00064-of-00352.parquet"}]]